|
[1] NEUSCHWANDER-TETRI BA. Non-alcoholic fatty liver disease[J]. BMC Medicine, 2017, 15 (1) :45.
|
|
[2] MICHELOTTI GA, MACHADO MV, DIEHL AM. NAFLD, NASH and liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :656-665.
|
|
[3] HOLMBERG SD, SPRADLING PR, MOORMAN AC, et al. Hepatitis C in the United States[J]. N Engl J Med, 2013, 368 (20) :1859-1861.
|
|
[4] COHEN JC, HORTON JD, HOBBS HH. Human fatty liver disease:Old questions and new insights[J]. Science, 2011, 332 (6037) :1519-1523.
|
|
[5] YOUNOSSI ZM, OTGONSUREN M, HENRY L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology, 2015, 62 (6) :1723-1730.
|
|
[6] PISCAGLIA F, SVEGLIATI-BARONI G, BARCHETTI A, et al.Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease:A multicenter prospective study[J]. Hepatology, 2016, 63 (3) :827-838.
|
|
[7] SINGAL AG, EL-SERAG HB. Hepatocellular carcinoma from epidemiology to prevention:Translating knowledge into practice[J].Clin Gastroenterol Hepatol, 2015, 13 (12) :2140-2151.
|
|
[8] WONG RJ, CHEUNG R, AHMED A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U. S.[J]. Hepatology, 2014, 59 (6) :2188-2195.
|
|
[9] TURNBAUGH PJ, LEY RE, MAHOWALD MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest[J]. Nature, 2006, 444 (7122) :1027-1031.
|
|
[10] WU WKK, ZHANG L, CHAN MTV. Autophagy, NAFLD and NAFLD-related HCC[J]. Adv Exp Med Biol, 2018, 1061:127-138.
|
|
[11] ZHU L, BAKER SS, GILL C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients:A connection between endogenous alcohol and NASH[J]. Hepatology, 2013, 57 (2) :601-609.
|
|
[12] MIE L, VALENZA V, LA TORRE G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J]. Hepatology, 2009, 49 (6) :1877-1887.
|
|
[13] SZABO G, CSAK T. Inflammasomes in liver diseases[J]. J Hepatol, 2012, 57 (3) :642-654.
|
|
[14] JIAO N, BAKER SS, CHAPA-RODRIGUEZ A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J]. Gut, 2018, 67 (10) :1881-1891.
|
|
[15] JIA W, XIE G, JIA W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15 (2) :111-128.
|
|
[16] MA C, HAN M, HEINRICH B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360 (6391) :eaan5931.
|
|
[17] PURI P, DAITA K, JOYCE A, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids[J]. Hepatology, 2017.[Epub ahead of print]
|
|
[18] KALHAN SC, GUO LN, EDMISON J, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease[J]. Metabolism, 2011, 60 (3) :404-413.
|
|
[19] XIE G, WANG X, LIU P, et al. Distinctly altered gut microbiota in the progression of liver disease[J]. Oncotarget, 2016, 7 (15) :19355-19366.
|
|
[20] LOO TM, KAMACHI F, WATANABE Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity[J]. Cancer Discov, 2017, 7 (5) :522-538.
|
|
[21] WEISBERG SP, MCCANN D, DESAI M, et al. Obesity is associated with macrophage accumulation in adipose tissue[J]. J Clin Invest, 2003, 112 (12) :1796-1808.
|
|
[22] GOMES AL, TEIJEIRO A, BUREN S, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma[J]. Cancer Cell, 2016, 30 (1) :161-175.
|
|
[23] PIKARSKY E, PORAT RM, STEIN I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer[J].Nature, 2004, 431 (7007) :461-466.
|
|
[24] PARK EJ, LEE JH, YU GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6and TNF expression[J]. Cell, 2010, 140 (2) :197-208.
|
|
[25] ARAB JP, ARRESE M, TRAUNER M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease[J]. Annu Rev Pathol, 2018, 13:321-350.
|
|
[26] van der WINDT DJ, SUD V, ZHANG H, et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in non-alcoholic steatohepatitis[J]. Hepatology, 2018.[Epub ahead of print]
|
|
[27] WAN S, ZHAO E, KRYCZEK I, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells[J]. Gastroenterology, 2014, 147 (6) :1393-1404.
|
|
[28] QIAN BZ, LI J, ZHANG H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis[J]. Nature, 2011, 475 (7355) :222-225.
|
|
[29] FLECKEN T, SAROBE P. Tim-3 expression in tumour-associated macrophages:A new player in HCC progression[J]. Gut, 2015, 64 (10) :1502-1503.
|
|
[30] DONG P, MA L, LIU L, et al. CD86 (+) /CD206 (+) , Diametrically polarized tumor-associated macrophages, predict hepatocellular carcinoma patient prognosis[J]. Int J Mol Sci, 2016, 17 (3) :320.
|
|
[31] MINAMI K, HIWATASHI K, UENO S, et al. Prognostic significance of CD68, CD163 and Folate receptor-beta positive macrophages in hepatocellular carcinoma[J]. Exp Ther Med, 2018, 15 (5) :4465-4476.
|
|
[32] MA C, KESARWALA AH, EGGERT T, et al. NAFLD causes selective CD4 (+) T lymphocyte loss and promotes hepatocarcinogenesis[J]. Nature, 2016, 531 (7593) :253-257.
|
|
[33] SHALAPOUR S, LIN XJ, BASTIAN IN, et al. Inflammation-induced Ig A+cells dismantle anti-liver cancer immunity[J]. Nature, 2017, 551 (7680) :340-345.
|
|
[34] WOLF MJ, ADILI A, PIOTROWITZ K, et al. Metabolic activation of intrahepatic CD8+T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes[J].Cancer Cell, 2014, 26 (4) :549-564.
|
|
[35] SAXENA NK, SHARMA D, DING X, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells[J]. Cancer Res, 2007, 67 (6) :2497-2507.
|
|
[36] KITADE M, YOSHIJI H, KOJIMA H, et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats[J]. Hepatology, 2006, 44 (4) :983-991.
|
|
[37] SHARMA D, WANG J, FU PP, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis[J].Hepatology, 2010, 52 (5) :1713-1722.
|
|
[38] HUI X, GU P, ZHANG J, et al. Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promoting M2macrophage proliferation[J]. Cell Metab, 2015, 22 (2) :279-290.
|
|
[39] CAI D, YUAN M, FRANTZ DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NFkappaB[J]. Nat Med, 2005, 11 (2) :183-190.
|
|
[40] DAVILA JA, MORGAN RO, SHAIB Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States:A population based case control study[J]. Gut, 2005, 54 (4) :533-539.
|
|
[41] ENGELMAN JA. Targeting PI3K signalling in cancer:opportunities, challenges and limitations[J]. Nat Rev Cancer, 2009, 9 (8) :550-562.
|
|
[42] SCHUBBERT S, SHANNON K, BOLLAG G. Hyperactive ras in developmental disorders and cancer[J]. Nat Rev Cancer, 2007, 7 (4) :295-308.
|
|
[43] SHAN J, SHEN J, LIU L, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma[J]. Hepatology, 2012, 56 (3) :1004-1014.
|
|
[44] DEVHARE PB, RAY RB. Extracellular vesicles:Novel mediator for cell to cell communications in liver pathogenesis[J]. Mol Aspects Med, 2018, 60:115-122.
|
|
[45] WANG B, MAJUMDER S, NUOVO G, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice[J]. Hepatology, 2009, 50 (4) :1152-1161.
|
|
[46] CONTI AD, ORTEGA JF, TRYNDYAK V, et al. MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis[J].Oncotarget, 2017, 8 (51) :88517-88528.
|
|
[47] LEE S, ZHANG C, LIU Z, et al. Network analyses identify liverspecific targets for treating liver diseases[J]. Mol Syst Biol, 2017, 13 (8) :938.
|
|
[48] SALAMEH H, HANAYNEH MA, MASADEH M, et al. PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum[J]. J Clin Transl Hepatol, 2016, 4 (3) :175-191.
|
|
[49] KHLAIPHUENGSIN A, KIATBUMRUNG R, PAYUNGPORN S, et al. Association of PNPLA3 polymorphism with hepatocellular carcinoma development and prognosis in viral and non-viral chronic liver diseases[J]. Asian Pac J Cancer Prev, 2016, 16 (18) :8377-8382.
|
|
[50] ANSTEE QM, SETH D, DAY CP. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease[J]. Gastroenterology, 2016, 150 (8) :1728-1744. e7.
|
|
[51] SHEN J, TSOI H, LIANG Q, et al. Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma[J]. Oncogene, 2016, 35 (49) :6271-6280.
|
|
[52] ZHAO F. Dysregulated epigenetic modifications in the pathogenesis of NAFLD-HCC[J]. Adv Exp Med Biol, 2018, 1061:79-93.
|
|
[53] LI QB, ZHUO QB, CHEN L, et al. Research advances in treatment of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2015, 31 (7) :1135-1139. (in Chinese) 李强, 卓其斌, 陈良, 等.非酒精性脂肪性肝病的治疗进展[J].临床肝胆病杂志, 2015, 31 (7) :1135-1139.
|
|
[54] JING J, YU JF, ZHANG TF. Curative effect of Yerba Mate improving phlegm and blood stasis, and blood lipid level of NAFLD[J].Clin J Med Offic, 2017, 45 (7) :683-684. (in Chinese) 井静, 于京芳, 张铁峰.马黛茶改善非酒精性脂肪性肝病痰瘀互结证血脂水平疗效分析[J].临床军医杂志, 2017, 45 (7) :683-684.
|
|
[55] BURZA MA, PIRAZZI C, MAGLIO C, et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals[J]. Dig Liver Dis, 2012, 44 (12) :1037-1041.
|
|
[56] SINGAL AG, YOPP AC, GUPTA S, et al. Failure rates in the hepatocellular carcinoma surveillance process[J]. Cancer Prev Res (Phila) , 2012, 5 (9) :1124-1130.
|
|
[57] SANTI V, TREVISANI F, GRAMENZI A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival[J]. J Hepatol, 2010, 53 (2) :291-297.
|
|
[58] CAUCHY F, MEBARKI M, ALBUQUERQUE M, et al. Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome[J]. Gut, 2015, 64 (9) :1498-500.
|
|
[59] EL-SERAG HB, JOHNSON ML, HACHEM C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes[J]. Gastroenterology, 2009, 136 (5) :1601-1608.
|
DownLoad: